Press Release

Israel Generic Drugs Market to Gain from High Demand for Generic Drugs

Rapid technological advancements and the rising case of chronic and infectious diseases are expected to drive the Israel generic drugs market during the forecast period.

According to the TechSci Research report, “Israel Generic Drugs Market – By Region, Competition, Forecast, and Opportunities, 2028”, the Israel generic drugs market is anticipated to grow at a significant rate during the forecast period. Generic drugs are typically cheaper than brand-name drugs because they do not require the same level of investment in research and development, marketing, and patent protection. This makes them more affordable for consumers, insurers, and healthcare systems, allowing for cost savings. hence augmenting the growth of the market. The availability of generic drugs promotes healthy competition in the pharmaceutical market, which can lead to innovation and the development of new drugs.

When the patents of brand-name drugs expire, generic versions can enter the market, creating competition and potentially driving down prices. This can incentivize innovation among pharmaceutical companies to develop new and improved drugs to stay competitive, which is likely to boost the Israel generic drugs market over the forecast period. However, the issue of intellectual property (IP) rights and patent protection, low awareness, and education about generic drugs among patients, healthcare providers, and the general public, and limited coverage may hamper the growth of the Israel generic drugs market in the forecast period.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on the “Israel Generic Drugs Market


The Israel generic drugs market is segmented by type, application, drug delivery, distribution channel, and region

Based on type, the market is divided into pure generic drugs and branded generic drugs. The branded generic drugs segment is expected to witness a rise over the forecast period. This is attributed to the fact that branded generic drugs are prescription medications developed to be identical to a brand-name drug that has already been commercialized in dosage form, strength, administration method, quality, performance attributes, and intended use.

Based on application, the market is divided into CNS, cardiovascular, dermatology, genitourinary/hormonal, respiratory, rheumatology, diabetes, oncology, and others. The oncology segment is anticipated to grow at a faster rate during the forecast period. This is attributed to the growing cases of cancer due to changing lifestyles.

Based on drug delivery, the market is divided into oral, injectables, dermal/topical, and inhalers. The oral segment is anticipated to grow at a faster rate during the forecast period. This is attributed to its benefits, including non-invasiveness, patient compliance, and ease of drug administration.

Based on distribution channel, the market is divided into retail pharmacies and hospital pharmacies. The hospital pharmacies segment is expected to witness a rise over the forecast period. This is attributed to Retail pharmacists occasionally making changes based on the medications in stock, although they tend to concentrate more on common ailments and treatments. Hospital pharmacists typically handle more complicated cases, particularly those that call for patients to stay in the hospital for observation.

Major companies operating in the Israel generic drugs market are:

  • Vitamed Pharmaceutical Industries Ltd
  • Perrigo Israel Pharmaceuticals Ltd.
  • Taro Pharmaceutical Industries Ltd
  • Bonus BioGroup Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Rafa Laboratories ltd
  • Dexcel Pharma Technologies Ltd.
  • Unipharm Ltd
  • Fischer pharmaceuticals limited
  • Beit jala pharmaceuticals

 

Download Sample Report

Customers can also request 10% free customization on this report.

 

“The Central Hill Region” is expected to lead the generic drug market in Israel over the next few years, owing to the presence of good infrastructure and support from the government. Also, by providing affordable alternatives to expensive brand-name drugs, generic drugs can help ensure that patients can access the medication they need to manage their health conditions, and the utilization of generic drugs is often seen as a cost-effective strategy. Many healthcare systems and insurance plans incentivize or mandate the use of generic drugs to save costs. As healthcare cost containment efforts continue, the demand for generic drugs is likely to increase, driving the generic drug market in Israel through 2028,” said Mr. Karan Chechi, Research Director at TechSci Research, a research-based global management consulting firm.

Israel Generic Drugs Market, By Type (Pure Generic Drugs, Branded Generic Drugs), By Application (CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Rheumatology, Diabetes, Oncology, and Others), By Drug Delivery (Oral, Injectables, Dermal/Topical, and Inhalers), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies), By Region, Competition, Forecast & Opportunities, 2028 has evaluated the future growth potential of Israel generic drugs market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision-makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the Israel generic drugs market.


Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Web: https://www.techsciresearch.com

Relevant News